Search Results

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. announced the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therapeutics in an all-stock transaction.

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023.

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023.

Applied Molecular Transport Inc., a biopharmaceutical company, reported financial results for the first quarter ended March 31, 2023.

Applied DNA Sciences, Inc. announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC, will utilize the GenXys Health Care Systems suite of clinical decision support software for interpretation and reporting of ADCL’s New York State Department of Health-approved TR8™ pharmacogenomic test.

Applied Molecular Transport Inc. announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company.

Longhorn Vaccines and Diagnostics LLC announced today new data validating the company’s core diagnostic product, PrimeStore® Molecular Transport Medium (MTM), and its potential to increase access to Mycobacterium tuberculosis (TB) testing for children in remote and underserved areas and reduce time to diagnosis and initiation of life-saving treatment.

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, announced its participation at the following investor conferences.

The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.